Oxidative metabolism of lansoprazole by human liver cytochromes P450

L Pichard, R Curi-Pedrosa, C Bonfils, E Jacqz-Aigrain, J Domergue, H Joyeux, J Cosme, FP Guengerich and P Maurel

INSERM U-128, CNRS, Montpellier, France.

The aim of this work was to identify the form(s) of human cytochrome P450 (P450) involved in the hepatic biotransformation of lansoprazole to its two main metabolites, i.e., the sulfone and the hydroxy derivative. In liver microsomes, the production of the sulfone of lansoprazole correlated with the level of P450 3A4, cyclosporin oxidase, and the production of the hydroxy derivative, as well as of omeprazole sulfone. The production of hydroxylansoprazole moderately correlated with the level of P450 3A4, cyclosporin oxidase, and (S)- mephenytoin 4'-hydroxylase. The production of the sulfone and of the hydroxy derivative of lansoprazole was significantly inhibited by anti- P450 3A4 antibodies, by cyclosporin and ketoconazole, and by tolbutamide. Anti-P450 2C8 and 2C3 antibodies moderately inhibited the biotransformation of lansoprazole, whereas they completely inhibited (S)-mephenytoin 4'-hydroxylase activity under the same conditions. In primary cultures of human hepatocytes, the biotransformation of lansoprazole and the oxidation of cyclosporin were strongly increased by rifampicin and phenobarbital, whereas (S)-mephenytoin 4'- hydroxylation was not. beta-Naphthoflavone did not induce the formation of the sulfones but stimulated the production of hydroxylansoprazole. Among several forms of cDNA-expressed human P450s, 3A4 generated significant amounts of the sulfones of lansoprazole and omeprazole and 2C18 was active for the production of hydroxylansoprazole but inactive in the 4'-hydroxylation of (S)-mephenytoin. We conclude that P450 3A4 is the major enzyme involved in the production of the sulfone of lansoprazole and that this P450, as well as P450 2C18 and/or another 2C- related form, could contribute to the production of hydroxylansoprazole.

Volume 47, Issue 2, pp. 410-418, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K.-A. Kim, M.-J. Kim, J.-Y. Park, J.-H. Shon, Y.-R. Yoon, S.-S. Lee, K.-H. Liu, J.-H. Chun, M.-H. Hyun, and J.-G. Shin STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES Drug Metab. Dispos., October 1, 2003; 31(10): 1227 - 1234. [Abstract] [Full Text] [PDF]

				J.-M. Pascussi, S. Gerbal-Chaloin, J.-M. Fabre, P. Maurel, and M.-J. Vilarem Dexamethasone Enhances Constitutive Androstane Receptor Expression in Human Hepatocytes: Consequences on Cytochrome P450 Gene Regulation Mol. Pharmacol., April 13, 2001; 58(6): 1441 - 1450. [Abstract] [Full Text]

				T. Shimada, F. Tsumura, and H. Yamazaki Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone with Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes Drug Metab. Dispos., November 1, 1999; 27(11): 1274 - 1280. [Abstract] [Full Text]

				J.-W. Ko, N. Sukhova, D. Thacker, P. Chen, and D. A. Flockhart Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms Drug Metab. Dispos., July 1, 1997; 25(7): 853 - 862. [Abstract] [Full Text]

				D. Sutton, A. M. Butler, L. Nadin, and M. Murray Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 294 - 300. [Abstract] [Full Text]

				F. Jung, T. H. Richardson, J. L. Raucy, and E. F. Johnson Diazepam Metabolism by CDNA-Expressed Human 2C P450S. Identification of P4502C18 and P4502C19 as Low KM Diazepam N-Demethylases Drug Metab. Dispos., February 1, 1997; 25(2): 133 - 139. [Abstract] [Full Text]

				A. M. Butler and M. Murray Biotransformation of Parathion in Human Liver: Participation of CYP3A4 and its Inactivation during Microsomal Parathion Oxidation J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 966 - 973. [Abstract] [Full Text]